Healthcare Thought Leader & Visiting Research Fellow at the Paragon Health Institute, Kev Coleman, highlights key considerations to watch for AI healthcare policy under a Trump 2.0 administration.

To read more of Kev's research, please visit here.

Stay tuned for the Paragon consolidated AI page, and Kev's paper with Michael Penina from Duke University that will be announced at a later time.

For further insights, read Kev's paper "Healthcare AI Regulation: Guidelines for Maintaining Public Safety and Innovation", which can be found here.

This paper examines the main challenges of AI regulation in healthcare and the second part provides guidelines to help policymakers avoid misregulation.

Key Takeaways:

1. The key policy areas that must be addressed in AI healthcare policy are public safety and privacy while maintaining world leadership. AI healthcare policy will continue to evolve over the next two years.

2. AI healthcare places a greater reliance on data and post-market surveillance after approval. Implementing this new way of operating so that it does not restrict innovation and cause unnecessary costs is essential for the FDA to consider.

3. AI consists of various programming methodologies, each with different vulnerabilities depending on the context. Regulations must address subtypes of AI.

*Please note that this interview is informational and is not meant as an endorsement/support/advocacy.

Why is National Colorectal Cancer Awareness Month so important? Senior Vice President, Global Public Affairs at Guardant Health, Jenn Higgins, teaches us why.

To learn more about Guardant Health, visit their website here.
To learn more about Shield Cancer Screen, visit their website here.

A huge thank you to Melissa Marasco of Guardant Health for scheduling and making this happen. Thank you!

Key takeaways:

1. Since its inception in 2012, the goal of Guardant Health was to be the organization for the Continuum of Care, which includes people who have never had cancer, survivors, treatment, and monitoring.

2. With 50 million Americans unscreened for colorectal cancer, Shield Cancer Screen helps improve adherence and alleviates fears of screening.

3. Maximizing innovation and minimizing the regulatory burden will help companies get their technology products into the hands of patients.

*Please note that this interview is informational and is not meant as an endorsement/support/advocacy.

How can precision wellness and healthcare be made cheaper, safer, and more efficient in contrast to what is available on the market? Chief Executive Officer of EndoDNA, Len May, teaches us how it is possible.

To connect with Len, find him on LinkedIn here.
To learn more about EndoDna, visit their website here.
To learn more about Len's coaching services, visit his website here.
To listen to Len's podcast, "Everything is Personal", listen to his podcast here.
To buy Len's book, purchase his book here.

Key Takeaways:

1. The origin of EndoDNA started with Len's interest in plant genetics and human genomics and drove him into the precision health and wellness space in healthcare.

2. The goal of EndoDNA is to use their technology and AI to have a person's genotype to help design an individualized treatment plan that has a feedback loop that illustrates similar individuals that have undergone said individualized treatment plan, which proves it is efficacious.

3. Preventative measures are essential in reducing the cost of healthcare, such as the use of genetics and epigenetics. With the addition of AI, healthcare professionals will be able to better understand their patients, and insurance companies will reduce the burden on themselves.

*Please note that this interview is informational and is not meant as an endorsement/support/advocacy.